基金经理看好港股三大方向

Market Overview - The Hong Kong stock market has been experiencing fluctuations since October, with the Hang Seng Index rising over 1.6% on October 2, followed by three consecutive days of adjustment [1] - Global capital is flowing into various markets as the Federal Reserve begins a new round of interest rate cuts, benefiting the Hong Kong market due to its valuation advantages and close ties to the mainland economy [1][2] Fund Inflows - There is an expectation of increased capital inflow into the Hong Kong market, driven by public fund institutions favoring it and sustained buying from southbound funds [2] - The demand for undervalued stocks in the Hong Kong market from mainland investors is growing, indicating a strong interest in reallocation of global funds [2] Performance Trends - Quality Hong Kong companies are showing a strong upward trend in performance, with over 1,230 companies reporting revenue growth in the first half of 2025 [2] - The information technology and consumer discretionary sectors are leading the revenue growth, each exceeding 10% year-on-year growth, becoming key drivers for profitability in the Hong Kong market [2] Technology Sector Insights - The Hang Seng Technology Index has experienced increased volatility due to intensified competition among domestic internet firms and rising capital expenditures in AI [3] - Long-term prospects for the technology sector remain positive, with a shift in focus from hardware to AI applications and software, which are expected to benefit from ongoing advancements [3] Valuation and Investment Opportunities - The technology sector in Hong Kong is currently valued attractively, with the Hang Seng Technology Index's price-to-earnings ratio at 23.32, significantly below its historical average [3] - Emerging consumer sectors such as trendy toys, new tea drinks, and beauty products are expected to maintain high growth rates, attracting investor attention [4] Pharmaceutical Sector Outlook - The pharmaceutical sector, particularly in innovative drugs, is anticipated to see improved fundamentals as the Federal Reserve's rate cuts enhance financing activities [4] - Despite recent volatility, confidence in the innovative drug sector remains high, with expectations for business development activities to ramp up in the coming months [4]